Muscle maturation: implications for gene therapy.

[1]  L. Kunkel,et al.  The fate of individual myoblasts after transplantation into muscles of DMD patients , 1997, Nature Medicine.

[2]  Simon C Watkins,et al.  Gene transfer to muscle using herpes simplex virus-based vectors , 1997, Neuromuscular Disorders.

[3]  S. Li,et al.  Selection and use of ligands for receptor-mediated gene delivery to myogenic cells , 1997, Gene Therapy.

[4]  X. Liang,et al.  Spatial–temporal patterns of gene expression in mouse skeletal muscle after injection of lacZ plasmid DNA , 1997, Gene Therapy.

[5]  I. Kovesdi,et al.  Myoblast-Mediated Ex Vivo Gene Transfer to Mature Muscle , 1997 .

[6]  S. Kochanek,et al.  Persistence in muscle of an adenoviral vector that lacks all viral genes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[7]  J. Tremblay,et al.  Control of inflammatory damage by anti-LFA-1: increase success of myoblast transplantation. , 1997, Cell transplantation.

[8]  R. Cull.  Clinical neurophysiology by Jasper R. Daube, 1996, 533 pp. A Davis Company, Philadelphia, ISBN 0-8036-0073-9, £135.00 , 1997, Neuromuscular Disorders.

[9]  Simon C Watkins,et al.  LacZ gene transfer to skeletal muscle using a replication-defective herpes simplex virus type 1 mutant vector. , 1997, Human gene therapy.

[10]  Simon C Watkins,et al.  Viral gene delivery to skeletal muscle: insights on maturation-dependent loss of fiber infectivity for adenovirus and herpes simplex type 1 viral vectors. , 1997, Human gene therapy.

[11]  James M. Wilson,et al.  Recombinant adeno-associated virus for muscle directed gene therapy , 1997, Nature Medicine.

[12]  Simon C Watkins,et al.  The basal lamina is a physical barrier to herpes simplex virus-mediated gene delivery to mature muscle fibers , 1996, Journal of virology.

[13]  D. Brough,et al.  Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types , 1996, Nature Biotechnology.

[14]  R. Samulski,et al.  Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector , 1996, Journal of virology.

[15]  R. Balice-Gordon,et al.  In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. , 1996, Human gene therapy.

[16]  C. Gravel,et al.  Prevention of immune reactions triggered by first-generation adenoviral vectors by monoclonal antibodies and CTLA4Ig. , 1996, Human gene therapy.

[17]  J. Chamberlain,et al.  Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. , 1996, Human molecular genetics.

[18]  C. Caskey,et al.  A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[19]  L. Vitiello,et al.  Condensation of plasmid DNA with polylysine improves liposome-mediated gene transfer into established and primary muscle cells. , 1996, Gene therapy.

[20]  E. Svensson,et al.  Muscle-based gene therapy: realistic possibilities for the future. , 1996, Molecular medicine today.

[21]  Hanns Lochmüller,et al.  Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer. , 1996, Human gene therapy.

[22]  H. Blau,et al.  Muscle-mediated gene therapy. , 1995, The New England journal of medicine.

[23]  C. Gravel,et al.  FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. , 1995, Human gene therapy.

[24]  R. R. Rice,et al.  Myoblast transfer in the treatment of Duchenne's muscular dystrophy. , 1995, The New England journal of medicine.

[25]  Hanns Lochmüller,et al.  Cultured human myoblasts and myotubes show markedly different transducibility by replication-defective adenovirus recombinants. , 1994, Gene therapy.

[26]  G. Acsadi,et al.  Gene transfer into skeletal muscles by isogenic myoblasts. , 1994, Human gene therapy.

[27]  E. Engvall,et al.  Defective muscle basement membrane and lack of M-laminin in the dystrophic dy/dy mouse. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[28]  G. Acsadi,et al.  A differential efficiency of adenovirus-mediated in vivo gene transfer into skeletal muscle cells of different maturity. , 1994, Human molecular genetics.

[29]  J. Wolff,et al.  Pharmacological enhancement of in vivo foreign gene expression in muscle. , 1994, Gene Therapy.

[30]  B. Demeneix,et al.  Plasmid DNA is superior to viral vectors for direct gene transfer into adult mouse skeletal muscle. , 1993, Human gene therapy.

[31]  P. Tonali,et al.  Retroviral vector-mediated gene transfer into human primary myogenic cells leads to expression in muscle fibers in vivo. , 1993, Human gene therapy.

[32]  M. Perricaudet,et al.  Long–term correction of mouse dystrophic degeneration by adenovirus–mediated transfer of a minidystrophin gene , 1993, Nature genetics.

[33]  George Karpati,et al.  Myoblast transfer in duchenne muscular dystrophy , 1993, Annals of neurology.

[34]  B. Demeneix,et al.  Direct gene transfer into skeletal muscle in vivo: factors affecting efficiency of transfer and stability of expression. , 1993, Human gene therapy.

[35]  C. Richards,et al.  Results of a Triple Blind Clinical Study of Myoblast Transplantations without Immunosuppressive Treatment in Young Boys with Duchenne Muscular Dystrophy , 1993, Cell transplantation.

[36]  P. Briand,et al.  Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice , 1993, Nature.

[37]  G. Acsadi,et al.  Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. , 1992, Human molecular genetics.

[38]  T. Friedmann,et al.  Cytotoxicity of a replication-defective mutant of herpes simplex virus type 1 , 1992, Journal of virology.

[39]  J. Mandel,et al.  Adenovirus as an expression vector in muscle cells in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[40]  K. Davies,et al.  Retroviral‐mediated transfer of a dystrophin minigene into mdx mouse myoblasts in vitro , 1992, FEBS letters.

[41]  J. Leiden,et al.  Systemic delivery of recombinant proteins by genetically modified myoblasts. , 1991, Science.

[42]  H. Blau,et al.  Systemic delivery of human growth hormone by injection of genetically engineered myoblasts. , 1991, Science.

[43]  K. Davies,et al.  Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs , 1991, Nature.

[44]  A. Miller,et al.  Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection , 1990, Molecular and cellular biology.

[45]  P. Yurchenco,et al.  Assembly of Basement Membranes a , 1990, Annals of the New York Academy of Sciences.

[46]  L. Kunkel,et al.  Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts , 1989, Nature.

[47]  Simon C Watkins,et al.  Immunoelectron microscopic localization of dystrophin in myofibres , 1988, Nature.

[48]  S. Kochanek,et al.  Ex vivo gene transfer using adenovirus-mediated full-length dystrophin delivery to dystrophic muscles , 1998, Gene Therapy.

[49]  A. Picard,et al.  Gene transfer in regenerating muscle. , 1994, Human gene therapy.

[50]  Eric P. Hoffman,et al.  Dystrophin: The protein product of the duchenne muscular dystrophy locus , 1987, Cell.